A rginine, a semiessential amino acid playing important roles in multiple metabolic and cellular processes, is a substrate for arginases and NO synthases (NOS) (1) . Arginases convert L-arginine into urea and L-ornithine, the latter serving as a substrate for the synthesis of polyamines and L-proline. NOS enzymes use L-arginine for the production of NO and L-citrulline. In addition to competing for their shared substrate, the biochemical pathways involving arginases and NOS enzymes regulate each other via feedback mechanisms (2, 3) .
Mammals possess two arginases designated arginase 1 (Arg1) and arginase 2 (Arg2). Arg1 and Arg2 present 58% sequence identity at the amino acid level and are encoded by distinct genes (3) . They catalyze the same biochemical reaction but differ with respect to subcellular localization and tissue distribution (4) . Arg1 is a cytosolic enzyme expressed predominantly in the liver, where it functions as an enzyme in the urea cycle for the detoxification of ammonia. It also is expressed in nonhepatic tissues such as the breast, kidney, testis, salivary glands, and epidermis. Arg2 is instead localized in mitochondria and has a wide tissue distribution, being expressed most highly in the prostate, kidney, small intestine, and lactating mammary glands.
Arginases and arginine metabolism are involved in various normal biological processes as well as in diverse pathological conditions, including vascular, pulmonary, infectious, immunological, and neoplastic diseases (5, 6) . Two general functions of arginases have been defined in the immune system. First, changes in arginase activity can modulate phagocytic function by affecting NO production. Second, arginase-mediated arginine depletion can inhibit T cell responses. In particular, arginine depletion recently has been implicated in tumor immunobiology (6) (7) (8) . Several studies have highlighted a key role of arginine depletion resulting from increased arginase expression in the suppression of tumorspecific T cell responses (5, 6, (9) (10) (11) .
Most information on the expression and function of arginases in the immune system concerns Arg1 (12) . Arg1 expression is induced in macrophages by cAMP, LPS, and Th2 cytokines such as IL-4, IL-10, and IL-13 (13) (14) (15) (16) (17) (18) . Arg1 is also expressed in dendritic cells (DCs) and granulocytes (15, 19, 20) . It has been suggested that increased Arg1 expression in macrophages leads to enhanced uptake of arginine from the extracellular microenvironment and hence to an inhibition of T cell responses (9, 21, 22) . Arginine depletion induces downregulation of CD3z chain expression in activated T cells, leading to a deficiency in the TCR complex and the suppression of T cell proliferation (6, (22) (23) (24) (25) . In contrast to Arg1, little is known about the expression and function of Arg2 in the immune system. Arg2 expression has been documented in mouse macrophages but was not found to be significantly modulated by Th1 or Th2 cytokines (15, 22, 26, 27) . A recent report suggested that Arg2 expression can be induced moderately in mouse macrophages by stimulation with CpG plus IFN-g (28) .
It has become increasingly clear during the course of the past few years that microRNAs (miRNAs) exert critical functions in the development and function of the immune system. Specific miRNAs have been shown to modulate gene expression in various immune cell types. microRNA-155 (miR155) in particular was found to be a prominent player in the regulation of innate and adaptive immune responses (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) . Regulation of the maturation, function, and maintenance of DCs involves several specific miRNAs (37) . We and others recently demonstrated that miR155 is strongly induced in mouse and human DCs of various subtypes in response to a range of maturation signals and that it is required for efficient DC maturation and the activation of Ag-specific T cell responses (35, 36) . miR155 is encoded by the B cell integration cluster (BIC) gene. Various genes involved in DC function have been shown to be downregulated by miR155 (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) .
In this study, we identify Arg2 as a novel miR155 target in DCs. Experiments with mouse DCs exhibiting ectopic miR155 expression and DCs derived from miR155 2/2 mice demonstrated that miR155 represses the expression of Arg2. Bioinformatic and functional analyses confirmed that Arg2 mRNA is a direct target of miR155. Finally, in vitro and in vivo T cell activation assays demonstrated that deregulation of Arg2 expression in DCs leads to depletion of arginine in the extracellular milieu and thus induces a functional defect in miR155-deficient DCs. To our knowledge, this study provides the first evidence for posttranscriptional regulation of Arg2 and indicates that fine-tuning of Arg2 expression by miR155 in activated DCs is critical for their ability to drive T cell responses by controlling the availability of arginine in the extracellular environment. , OTII, OTII-CD45.1, and OTII-Rag2 2/2 mice have been described previously (29, 41) . Mice were bred under specific pathogen-free conditions and used for experiments at 8-10 wk of age. Experiments were performed with permission of the cantonal and national veterinary authorities.
Materials and Methods

Mice
Cells and medium
The mouse DC 2114 cell line and 293T cells were cultured as described previously (35, 42) . Mouse lung myofibroblasts were cultured under 5% CO 2 in a humidified incubator in DMEM supplemented with 10% FCS and 1000 U/ml penicillin and 1000 mg/ml streptomycin. Bone marrow plasmacytoid DCs (BM-pDCs) and BM-conventional DCs (cDCs) were derived from tibia and femur bone marrow suspensions from 8-to 10-wk-old mice as described previously (35 2 splenic DCs were purified by sorting with a FACSVantageSE (BD Biosciences). DC maturation was induced with 100 ng/ml LPS (Alexis), 0.05 mg/ml polyinosinic-polycytidylic acid (poly I/C) (Amersham Biosciences), 0.2 nM CpG ODN 1826 (Trilink Biotech), 10 mg/ml peptidoglycan (PGN) (Sigma-Aldrich), 500 ng/ml PAM 3 CSK 4 (InvivoGen), 200 ng/ml flagellin (InvivoGen), or 3 mg/ml imiquimod (InvivoGen). CD4 + T cells from spleen and lymph nodes of WT or OTII mice were purified using a CD4 + T cell isolation kit (Miltenyi Biotec). DMEM without arginine was purchased from Genaxxon Bioscience and supplemented with 4 mM MnCl 2 , 10% FCS, 1000 U/ml penicillin, and 1000 mg/ml streptomycin. L-Arginine-free DMEM or supernatants from vector or Arg2 transduced DC 2114 cells were supplemented with 400 mM L-arginine (Sigma-Aldrich).
Illumina expression profiling
Five hundred nanograms of total RNA was purified using TRIzol from sorted immature and mature CD11c + BM-cDCs and CD11c + B220 + BMpDCs from wild-type (WT) and miR155 2/2 mice. Labeling was performed using the Illumina TotalPrep RNA Amplification kit. Biotin-labeled cRNA was hybridized to Illumina mouse genome WG-6_V2 microarrays. Arrays were washed, stained, and scanned using Illumina's BeadStation 500 system and an iScan instrument equipped with Autoloader2. Data were normalized and analyzed using Illumina Beadstudio 3.1.3 (background correction and quantile normalization without scaling). Microarray data reported in our study have been deposited in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress/) under accession numbers E-MTAB-1527 (Supplemental Fig. 1A ).
Lentiviral transductions
Arg2 cDNA was amplified by PCR (primers 59-ATGACGTTTAAACGC-CACCATGTTCCTGAGGAGCAGC-39 and 59-ATGACGTTTAAACC-TAAATTCTCACACATTCTTC-39) and cloned into the lentiviral pWPI vector, which contains a GFP expression cassette for assessing transduction efficiency (35) . BIC and mutated BIC lentiviral vector constructs have been described previously. Transduction of DC 2114 cells and BM-cDCs was performed as previously described (35) and assessed on the basis of GFP expression.
Quantitative RT-PCR
Real-time PCR of mouse miR155 was performed using the miRCURY LNA Universal RT microRNA PCR system according to the manufacturer's instructions (Exiqon). miR155 expression of was normalized using U6 snRNA and 5S rRNA (Exiqon). Mouse mRNAs were quantified by quantitative RT-PCR (qRT-PCR) as described previously (35) . Expression was normalized using b-actin mRNA, TBP mRNA, or 18S rRNA. Primer sequences were as follows: mouse Arg2 forward (59-CTGTGTCAC-CATGGGAGGAG-39) and reverse (59-GCATGAGCATCAACCCAGAT-39); mouse Arg1 forward (59-ATGAAGAGCTGGCTGGTGTG-39) and reverse (59-GCCAGAGATGCTTCCAACTG-39). Primers sequences for mouse BIC, IL-6, and IL12-p40 have been reported previously (35) .
Luciferase reporter assays
The 39-untranslated regions (UTRs) of mouse Arg2 (270 bp) and Arg1 (402 bp) mRNAs were amplified by PCR and inserted downstream of the Renilla luciferase gene in the dual luciferase reporter plasmid psiCHECK-2 (Promega). The QuikChange Multi Site-Directed Mutagenesis kit (Stratagene) was used to mutate the miR155 binding site. Luciferase reporter assays were performed as described previously (32) .
Flow cytometry
Flow cytometry was performed with a FACSCalibur (BD Biosciences) and analyzed with WinMDI software. Staining was performed in the presence of saturating concentrations of 2.4G2 anti-FcgRII/III mAbs. Abs were as follows: anti-CD4 (RM4-5), anti-CD45R/B220 (RA3-6B2), anti-CD11c (N418), anti-CD69 (H1.2F3), anti-CD44 (IM7), anti-CD247 (CD3 z) (6B10.2), anti-Va2 TCR (B20.1), anti-CD45.1 (A20), and anti-AnnexinV (BioLegend). Intracellular staining was done with the Fixation/Permeabilization kit (eBioscience). T cell proliferation was assessed by flow cytometry using an anti-human Ki67 staining kit (BD Biosciences).
Western blotting
Protein extracts were fractionated by SDS-PAGE, and Western blotting was performed using anti-mouse Arg2 (sc-20151; Santa Cruz Biotechnology), anti-mouse Arg1 (sc-20150; Santa Cruz Biotechnology), and anti-tubulin (B-5-1-2; Sigma-Aldrich).
T cell stimulation and proliferation
Purified CD4
+ T cells were activated in vitro with anti-CD3ε (2 mg/ml; 145-2C11) and anti-CD28 (2 mg/ml; 37.51). Purified CD4 + T cells were labeled with 0.5 mM CFSE (BioLegend). 
ELISAs
Mouse IL6, TNF, IL12-p40, and IL-10 were quantified in culture supernatants using an ELISA kit, according to the manufacturer's instructions (eBioscience).
Immunofluorescence microscopy
Cells were seeded on glass coverslips, cultured for 24 h in the absence or presence of CpG, fixed for 10 min at room temperature with 1% paraformaldehyde in PBS, and stained with anti-Tom-20 (a gift from L. Scorrano, University of Padua, Padua, Italy), anti-mouse Arg2, and DAPI. Cells were observed with a Zeiss Axiocam microscope using Axiovision software.
Enzymatic assays
Arginase activity was measured using the QuantiChrom Arginase Assay kit (BioAssay Systems). Arginine concentrations were determined using the PD-direct Media Analytical Services (Invitrogen). NO3 2 (nitrate) and NO2
2
(nitrite) concentrations were measured using Griess reagent and a total nitrate/nitrite colorimetric assay (Cayman Chemical) following the reduction of nitrate to nitrite. Absorbance was measured at 550 nm using a plate reader, and nitrite concentrations were determined using NaNO 2 as standard.
Lung histology and collagen quantification
Paraffin-embedded lung sections (5 mm) were stained with Masson Trichrome and observed in a Zeiss Axiocam microscope using Axiovision software. For collagen quantification, lungs were homogenized in 1 ml 0.5 M acetic acid containing 0.1 mg/ml pepsin overnight, and soluble collagen was measured using the Sircol collagen assay (Biocolor), according to the manufacturer's instructions. Data are expressed as micrograms of collagen per milligram of total protein.
Statistical analysis
The p values were calculated using the Student t test with two-tailed distribution and two-sample unequal variance parameters.
Results
Identification of mRNAs regulated by miR155 in DCs
Microarray experiments were performed to compare the gene expression profiles exhibited by immature and activated BM-cDCs and BM-pDCs from WT and miR155 2/2 mice (Supplemental Fig.   1A ). DCs were activated for 4 or 24 h with LPS (BM-cDCs) or imiquimod (BM-pDCs). Well-established miRNA binding site prediction criteria were used to generate a list of potential targets of miR155 ( Fig. 1A ) (43) . The list of putative targets was compared with the set of mRNAs that exhibited elevated expression in activated BM-cDCs and BM-pDCs from miR155 2/2 mice. This identified target mRNAs likely to be regulated by miR155 in BM-cDCs and/or BM-pDCs (Fig. 1A) . Only four of these mRNAs (Arg2, Csnk1g2, Hn1l, and Tspan14) were found to be potential miR155 targets in both BM-cDCs and BM-pDCs (Fig. 1A , Table I ). Given the growing interest in the role of arginine metabolism in the immune system, we focused our attention on the Arg2 gene.
Regulation of Arg2 expression by miR155 in DCs
Microarray signal intensities corresponding to Arg2 were significantly increased relative to WT in miR155 2/2 BM-cDC and BMpDCs after 4 and 24 h of stimulation with LPS or imiquimod, respectively (Fig. 1B, Supplemental Fig. 1A ). qRT-PCR experiments confirmed that the induction of Arg2 mRNA expression was significantly elevated in miR155 2/2 BM-cDCs and BM-pDCs compared with their WT counterparts (Fig. 1C, Supplemental Fig. 1B) . Maturation was controlled by measuring the induction of IL6 mRNA, IL12-p40 mRNA, and the miR155 precursor RNA (BIC). Arg2 protein expression and arginase activity were quantified in WT and miR155 2/2 BM-cDCs and BM-pDCs following exposure to LPS or imiquimod, respectively. Arg2 protein was markedly increased in miR155 2/2 BM-cDCs and BM-pDCs compared with WT DCs (Fig. 2A, Supplemental Fig. 1C ). Arginase activity also was increased strongly and significantly in miR155 2/2 BM-cDCs and BM-pDCs (Fig. 2B ). This increase in arginase activity resulted from elevated Arg2 expression because Arg1 mRNA and protein levels were not deregulated in miR155 2/2 BM-cDCs and absent in BM-pDCs ( Fig. 2A, Supplemental Fig. 2 ). Deregulated Arg2 expression was confirmed in miR155 2/2 BMcDCs following exposure to the TLR3 ligand poly I/C, the TLR2 ligands PGN and PAM 3 CSK 4 , the TLR7 ligand imiquimod, and the TLR9 ligand CpG. As observed following exposure to the TLR4 ligand LPS, Arg2 expression was significantly derepressed in miR155 2/2 BM-cDCs exposed to these stimuli (Fig. 2C) . Significantly increased Arg2 expression also was observed in total splenic miR155 2/2 DCs stimulated with LPS, and splenic CD8 -and CD8 + miR155 2/2 DCs stimulated with CpG (Fig. 2C , right panels).
Because arginases and NOS enzymes compete for the same substrate, increased arginase activity is expected to lead to reduced NO production. NO production was indeed significantly impaired in activated miR155 2/2 BM-cDCs (Supplemental Fig. 3 ). This was not because of reduced inducible NOS expression (data not shown). Collectively, these results suggest that Arg2 expression and arginase activity are repressed by miR155 in all DC subsets examined and in response to all maturation stimuli tested.
Deregulated Arg2 expression in the lungs of miR155 2/2 mice miR155 2/2 mice develop a lung pathology characterized by increased airway remodeling and bronchiolar collagen deposition (29) . This phenotype could be a consequence of deregulated Arg2 expression because arginase activity regulates the production of collagen via increased proline synthesis (44) . We confirmed that a marked accumulation of collagen is evident around lung bronchioles in miR155 2/2 mice (Fig. 3A) . Total collagen was significantly increased in the lungs of miR155 2/2 mice compared with WT mice (Fig. 3B) . We next assessed Arg2 expression in the lungs of WT and miR155 2/2 mice. Significant increases in arginase activity and Arg2 protein were observed in total lung extracts from miR155 2/2 mice (Fig. 3C ). Because collagen is mainly produced by myofibroblasts, mir155 expression, Arg2 expression, and arginase activity were assessed in myofibroblasts purified from miR155 2/2 and WT lungs. WT myofibroblasts expressed both mature miR155 and the BIC miR155 precursor RNA (Fig. 3D ).
Significant increases in Arg2 mRNA, Arg2 protein, and arginase activity were evident in lung myofibroblasts from miR155 2/2 mice (Fig. 3D) , suggesting that collagen deposition in the lungs of miR155 2/2 mice correlates with derepressed Arg2 expression in myofibroblasts. These results indicate that the control of Arg2 expression by miR155 is not restricted to DCs.
Arg2 mRNA is a direct target of miR155
Arg2 mRNA was analyzed for the presence of potential miR155 binding sites by computational approaches relying on well-established criteria for identifying miRNA target sites (43) . A likely miR155 binding site was identified in the 39-UTR of mouse Arg2 mRNA (Fig. 4A) . This site contains a seven-nucleotide sequence exhibiting high complementarity to the "seed" region situated at the 59-end (positions 2-8) of miR155. We generated a luciferase reporter construct in which the 39-UTR from Arg2 mRNA was inserted downstream of the luciferase gene (WT-Arg2). A matching control construct was generated by mutating the seed region of the potential miR155 binding site (Mut-Arg2). We also generated a control construct containing the 39-UTR from Arg1 mRNA (WT-Arg1). Activities of the WT-Arg2, WT-Arg1, and Mut-Arg2 constructs were measured after transfection into 293T cells in conjunction with either the miR155 precursor or a BIC (miR155) expression vector. Luciferase activity of the WT-Arg2 construct was strongly reduced when cotransfected with the miR155 precursor and BIC expression vector (Fig. 4B) . In contrast, no reductions were observed for either the Mut-Arg2 or WT-Arg1 constructs. These results confirm that miR155 targets Arg2 mRNA by binding to a specific site in its 39-UTR. To further confirm that Arg2 expression is controlled by miR155, we transduced WT and miR155 2/2 BM-DCs with a lentiviral vector containing the BIC (miR155) gene or a control vector containing a mutated BIC gene lacking the miR155 sequence (35) . Uninduced WT BM-DCs transduced with the BIC expression Means and SDs were derived from at least six mice per group. *p , 0.05, **p , 0.01.
vector exhibited a 5-fold increase in mature miR155, which is within a physiological range compared with the 13-fold increase observed in WT BM-DCs after 24 h of stimulation with LPS (Fig. 5A ). The impact of enforced miR155 expression on Arg2 mRNA levels was assessed in the transduced DCs prior to and after exposure to LPS (Fig. 5A ). Arg2 mRNA levels were significantly decreased in BIC-transduced WT and miR155 2/2 BMDCs (Fig. 5A ). The same approach was used to assess the impact of enforced BIC expression on Arg2 mRNA levels in the mouse DC 2114 cell line (Fig. 5B ). Arg2 mRNA levels were again significantly decreased by miR155 overexpression in unstimulated or CpG-treated BIC-transduced DC 2114 cells (Fig. 5B ).
Functional consequences of deregulated Arg2 expression
To study the biological relevance of appropriately-regulated Arg2 expression in DCs, we studied the consequences of deregulating Arg2 expression in these cells. Ectopic Arg2 expression was induced in DC 2114 cells using a lentiviral vector directing the expression of Arg2 under the control of heterologous promoter and 39-UTR regions. Transduction efficiency was assessed by analyzing vector-encoded GFP expression by flow cytometry (Fig. 6A) . Immunofluorescence experiments demonstrated that the overexpressed Arg2 was correctly localized in mitochondria, as assessed by colocalization with the mitochondrial marker Tom-20 (Fig. 6B) . Mitochondrial localization was not affected by stimulation with CpG. Western blot analysis confirmed the increased abundance of Arg2 protein in Arg2-transduced DC 2114 cells (Fig. 6C) . A 16-fold increase in arginase activity was observed in the Arg2-transduced DC 2114 cells (Fig. 6D ). This fold increase is within the range of that observed in miR155
2/2 cells (3-to 30-fold; Fig. 2B ). Finally, overexpression of Arg2 resulted in a selective depletion of arginine from the culture medium (Fig. 6E) . Lowering arginine concentrations in the culture medium leads to impaired proliferation of WT anti-CD3/anti-CD28-activated CD4 + T cells and downregulation of the CD3 z-chain (Supplemental Fig.  4A ). We therefore investigated whether overexpression of Arg2 in DC 2114 cells has an impact on their ability to induce T cell proliferation. Activated T cells were cultured in supernatants derived from control and Arg2-transduced DC 2114 cells, and proliferating Ki67 + T cells or CFSE-labeled T cells were quantified by flow cytometry. Proliferation was significantly reduced when T cells were cultured in supernatants from Arg2-transduced DC 2114 cells compared with supernatants from vector-transduced DC 2114 cells (Fig. 6F, Supplemental Fig. 4B ). In contrast, no reduction in the frequency of activated CD69 + T cells was observed (Fig. 6F ). Reduced T cell proliferation was not associated with increased T cell apoptosis, because the frequency of AnnexinV +
7AAD
+ cells was comparable between T cells cultured in supernatants from Arg2 and vector-transduced DC 2114 cells (Supplemental Fig. 4B ). The same experimental setting was used to examine T cell proliferation in supernatants derived from WT and miR155 2/2 BM-cDCs. Proliferation was significantly impaired when the T cells were cultured in supernatants from miR155 2/2 BM-cDCs (Fig. 6G ).
To determine whether arginine depletion was responsible for the impaired T cell proliferation, we supplemented supernatants from the vector-and Arg2-transduced DC 2114 cells with exogenous L-arginine. T cell proliferation was significantly rescued, albeit only partially, by the addition of L-arginine to supernatants from the Arg2-transduced DC 2114 cells (Fig. 6H) . Furthermore, to test whether Arg2 overexpression might alter cytokine production by DCs, we compared CpG-induced IL-6, IL12-p40, IL-10, and TNF production by Arg2-and vector-transduced DC 2114 cells. No significant difference in the induction of these cytokines was observed ( Supplemental Fig. 4C ).
The impact of Arg2-mediated arginine depletion on T cell proliferation was further assessed by means of in vivo Ag presentation assays, based on the adoptive transfer of OTII T cells and OVA-loaded control or Arg2-transduced DC 2114 cells. Splenic OTII T cell proliferation and activation were examined by flow cytometry 48 and 72 h after transfer. In the absence of DC 2114 transfer, only a basal level (1-2%) of OTII T cell proliferation was observed. Both vector-and Arg2-transduced DC 2114 cells induced significant proliferation (Fig. 7A) . However, OTII T cell proliferation was significantly impaired in the case of transfer of Arg2-transduced DC 2114 cells (Fig. 7A, 7C ). This impaired proliferation correlated with significant downregulation of the CD3 z-chain (Fig. 7B) . No change in expression of the T cell activation markers CD69 and CD44 was observed (data not shown). In addition, no change in T cell apoptosis was observed (Fig. 7C ). These results demonstrate that arginine depletion induced by deregulated Arg2 expression leads to impaired proliferation of CD4 + T cells in vivo.
Discussion
We report in this paper that repression of Arg2 expression by miR155 in activated DCs is required for avoiding excessive arginine depletion in the extracellular microenvironment and is consequently critical for the ability of mature DCs to prime T cell responses. Taken together with prior studies addressing the role of miR155 in DCs, our results establish miR155 as a central regulator of DC maturation and function. Recent years have witnessed a growing interest in the immunomodulatory functions of amino acid metabolism. The main enzymatic pathways involved in this process of "immunomodulation by starvation" are tryptophan catabolism by IDO and arginine catabolism by arginases and NOS enzymes (6, 45) . Studies on the immunoregulatory roles of arginine depletion have focused mainly on arginase expression by macrophages, myeloid-derived suppressor cells (MDSCs), and tumor cells (8, 46, 47) . Our results demonstrate that the regulation of arginase-mediated arginine depletion also makes key contributions to DC function (Fig. 7) .
Studies on the functional relevance of arginase expression by cells of the immune system have focused almost exclusively on Arg1, which is the major arginase expressed in macrophages, MDSCs, and granulocytes (12, 18, 20) . Data on Arg2 are scarcer.
It is expressed at a basal level in macrophages, where it is not modulated to a major extent by extracellular signals, such as Th1 and Th2 cytokines (15) . Certain infections, such as Helicobacter pylori, induce Arg2 expression in macrophages (48) . We show in this study that Arg2 is the dominant arginase in DCs. Arg2 mRNA and protein expression are markedly induced during maturation in all DC subtypes tested, including BM-cDCs, BM-pDCs, splenic DCs, and the CD8 + DC 2114 cell line (Figs. 1, 2) . In sharp contrast, Arg1 expression is not increased during maturation of BM-cDCs and is absent in BM-pDCs (Supplemental Fig. 2 ). Derepressed Arg2 expression in activated BM-cDCs and BM-pDCs from miR155 2/2 mice leads to a strong increase in total arginase activity (Fig. 2B) . Similarly, overexpression of Arg2 in DC 2114 cells to levels comparable to those observed in miR155 2/2 DCs strongly increases total arginase activity and arginine consumption (Fig. 6D, 6E ). Collectively, these results indicate that the overall arginase activity in DCs is determined mainly by Arg2. Arg1 appears to make only a minor contribution. The role of Arg2 in modulating immune responses has therefore been underestimated and merits further investigation. With the exception of elevated plasma arginine levels, no obvious phenotypes have been reported for Arg2-deficient mice (49) . However, their immune system has not been examined in detail. One report has shown that Arg2 2/2 macrophages exhibit increased NO production and decreased apoptosis induced by H. pylori (48) . Because Arg2 is the dominant arginase in DCs, a potential immunological phenotype in Arg2 2/2 mice deserves to be investigated. It should be emphasized that a deficiency in Arg2 is not expected to result in the same DC defects observed for Arg2 overexpression, namely increased arginine consumption and an impaired ability to induce T cell responses. However, other defects could well result from strongly reduced arginase activity in DCs. We show in this study that Arg2 expression is repressed by binding of miR155 to a specific target site localized within the 39-UTR of its mRNA (Fig. 4) . To our knowledge, this constitutes the first demonstration that arginase activity can be modulated at the posttranscription level by a miRNA. Until now, no miRNAs had been implicated in the regulation of Arg2 expression. In the case of Arg1, one study reported that hepatocyte-specific deletion of the gene encoding Dicer, the main miRNA processing enzyme, affects proper localization of Arg1 in the liver (50) . The latter suggests a potential direct or indirect role for miRNAs in regulating Arg1 function, although the precise miRNAs that might be implicated have not been identified.
Functionally relevant regulation of Arg2 expression by miR155 is not restricted to DCs. We show in this paper that lung pathology exhibited by miR155 2/2 mice can be attributed to derepressed Arg2 expression in lung myofibroblasts (Fig. 3D) . Perturbed control of Arg2 repression by miR155 should therefore be considered as a potential parameter contributing to the pathogenesis of lung diseases associated with deregulated collagen production. Further examination of Arg2 and miR155 expression in other healthy and diseased tissues may shed light on additional physiological functions and pathogenic mechanisms in which miR155-controlled Arg2 expression is implicated. Arginase activity is believed to contribute to the immunosuppressive functions of tumor associated macrophages (9), DCs (51), MDSCs, and the tumor cells themselves (8, 46, 47) . Increased arginase activity is thought to promote tumor development and progression by inducing arginine depletion and hence an inhibition of T cell-mediated antitumor responses. Arginase inhibitors have indeed been found to exhibit promising therapeutic effects in mouse tumor models (9, 52, 53) . Altered repression of Arg2 by miR155 could therefore contribute to the escape of tumors from immunosurveillance. Our results raise the hope that manipulating the expression or activity of Arg2 and/or miR155 could be of therapeutic value for the treatment of cancer.
